| Literature DB >> 26887344 |
X Liu1, Z Yue1, J Yu2,3,4,5, E Daguindau2,3,4,5, K Kushekhar2,3,4,5, Q Zhang6, Y Ogata6, P R Gafken6, Y Inamoto7,8, A Gracon9, D S Wilkes9, J A Hansen7,10, S J Lee7,10, J Y Chen1, S Paczesny2,3,4,5.
Abstract
Improved diagnostic methods are needed for bronchiolitis obliterans syndrome (BOS), a serious complication after allogeneic hematopoietic cell transplantation (HCT) and lung transplantation. For protein candidate discovery, we compared plasma pools from HCT transplantation recipients with BOS at onset (n = 12), pulmonary infection (n = 16), chronic graft-versus-host disease without pulmonary involvement (n = 15) and no chronic complications after HCT (n = 15). Pools were labeled with different tags (isobaric tags for relative and absolute quantification), and two software tools identified differentially expressed proteins (≥1.5-fold change). Candidate proteins were further selected using a six-step computational biology approach. The diagnostic value of the lead candidate, matrix metalloproteinase 3 (MMP3), was evaluated by enzyme-linked immunosorbent assay in plasma of a verification cohort (n = 112) with and without BOS following HCT (n = 76) or lung transplantation (n = 36). MMP3 plasma concentrations differed significantly between patients with and without BOS (area under the receiver operating characteristic curve 0.77). Consequently, MMP3 represents a potential noninvasive blood test for diagnosis of BOS. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.Entities:
Keywords: basic (laboratory) research/science; biomarker; bone marrow/hematopoietic stem cell transplantation; bronchiolitis obliterans (BOS); lung transplantation/pulmonology; translational research/science
Mesh:
Substances:
Year: 2016 PMID: 26887344 PMCID: PMC4956556 DOI: 10.1111/ajt.13750
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086